European journal of pharmacology · 2026
Genomic and AI-driven discovery in chronic prostatitis: Causal role of ITPR3 and therapeutic repurposing of raloxifene.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Yutong, Dong Xuan, Sun Ruixu, Gao Liangmeng, Song Xingyu, Huang Zhibin, Zuo Ling, Liu Hongwei
Аннотация
BACKGROUND: This study employed an integrative multi-omics strategy to investigate the potential role of inositol 1,4,5-trisphosphate receptor type 3 (ITPR3) in chronic prostatitis and to identify potential therapeutic targets and drugs using a mendelian randomization (MR)-proteomics causal inference framework.
OBJECTIVES: To investigate the potential role of ITPR3 in chronic prostatitis and to identify potential therapeutic targets and drugs.
METHODS: We harmonized multi-omics data from eQTLGen (blood eQTLs, n = 31,684), UKB-PPP (plasma pQTLs, n = 54,219), and FinnGen (GWAS for chronic prostatitis: the discovery cohort 4160 cases/130,139 controls and replication cohort 4743 cases/141,300 controls). A two-sample bidirectional MR approach was applied to assess causal relationships between druggable genes and chronic prostatitis. The SMR-HEIDI analysis was conducted to exclude linkage disequilibrium confounding, followed by co-expression network construction and functional enrichment analysis to explore biological pathways. ITPR3 inhibitors were predicted using the DSigDB platform, with binding affinity evaluated through molecular docking and ADME properties analyzed via the SwissADME.
RESULTS: MR analysis revealed that each 1-standard deviation increase in genetically predicted ITPR3 expression was associated with a 32.8 % higher risk of chronic prostatitis (OR = 1.328, 95 % CI: 1.108-1.702, P < 0.001), which was further validated by SMR-HEIDI testing (HEIDI P > 0.05). Functional enrichment analysis suggested that ITPR3 may contribute to chronic prostatitis progression through TGF-β/SMAD7 inflammatory pathway and calcium signaling dysregulation, while co-expression network analysis indicated its association with Th17 cell differentiation. Molecular docking demonstrated high binding affinity between raloxifene and ITPR3, and ADME profiling indicated favorable oral bioavailability without significant CYP450 inhibition risk, complying with Lipinski's rule.
CONCLUSION: ITPR3 is a novel therapeutic target for chronic prostatitis, and the computational repurposing of raloxifene as its inhibitor warrants further experimental investigation. These findings provide new insights for developing clinical interventions in chronic prostatitis.
OBJECTIVES: To investigate the potential role of ITPR3 in chronic prostatitis and to identify potential therapeutic targets and drugs.
METHODS: We harmonized multi-omics data from eQTLGen (blood eQTLs, n = 31,684), UKB-PPP (plasma pQTLs, n = 54,219), and FinnGen (GWAS for chronic prostatitis: the discovery cohort 4160 cases/130,139 controls and replication cohort 4743 cases/141,300 controls). A two-sample bidirectional MR approach was applied to assess causal relationships between druggable genes and chronic prostatitis. The SMR-HEIDI analysis was conducted to exclude linkage disequilibrium confounding, followed by co-expression network construction and functional enrichment analysis to explore biological pathways. ITPR3 inhibitors were predicted using the DSigDB platform, with binding affinity evaluated through molecular docking and ADME properties analyzed via the SwissADME.
RESULTS: MR analysis revealed that each 1-standard deviation increase in genetically predicted ITPR3 expression was associated with a 32.8 % higher risk of chronic prostatitis (OR = 1.328, 95 % CI: 1.108-1.702, P < 0.001), which was further validated by SMR-HEIDI testing (HEIDI P > 0.05). Functional enrichment analysis suggested that ITPR3 may contribute to chronic prostatitis progression through TGF-β/SMAD7 inflammatory pathway and calcium signaling dysregulation, while co-expression network analysis indicated its association with Th17 cell differentiation. Molecular docking demonstrated high binding affinity between raloxifene and ITPR3, and ADME profiling indicated favorable oral bioavailability without significant CYP450 inhibition risk, complying with Lipinski's rule.
CONCLUSION: ITPR3 is a novel therapeutic target for chronic prostatitis, and the computational repurposing of raloxifene as its inhibitor warrants further experimental investigation. These findings provide new insights for developing clinical interventions in chronic prostatitis.